Indivior Announces Q1 2023 Financial Results

Rhea-AI Summary

Indivior PLC reported its financial results for the first quarter of 2023, ending March 31, 2023. The earnings release, along with an investor presentation and a live webcast, is available on the company’s website.

Indivior aims to transform substance use disorders (SUD) into treated chronic diseases by leveraging its global portfolio of opioid use disorder treatments. The company employs over 1,000 people and operates across 39 countries, underscoring its commitment to providing evidence-based treatment options.

For more details, access the earnings release and investor presentation via the provided links.

Positive

• Strong commitment to addressing substance use disorders with a global portfolio.
• Employed over 1,000 individuals, indicating robust operational capacity.

Negative

• None.

SLOUGH, U.K., and Richmond, Va., April 27, 2023 /PRNewswire/ -- Indivior PLC (LSE: INDV) today announced its financial results for the period ending March 31, 2023. The earnings release, investor presentation and webcast are available at www.indivior.com.

• The earnings release can be found at www.indivior.com/en/media/press-releases
• The investor presentation can be found at www.indivior.com/investors

There will be a live webcast presentation at 13:00 BST (8:00 am EST) hosted by Mark Crossley, CEO. The details are below.

Webcast link: https://edge.media-server.com/mmc/p/qjdd6559

Participants may access the presentation telephonically by registering with the following link: https://register.vevent.com/register/BIa24873f5a1524c73b34c473b7761725f

(Please note this is a change from prior calls - registrants will have an option to be called back directly immediately prior to the call or be provided a call-in # with a unique pin code following their registration) 

About Indivior

Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD) and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid use disorder treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and cooccurring disorders of SUD. Headquartered in the United States in Richmond, VA, Indivior employs more than 1,000 individuals globally and its portfolio of products is available in 39 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.

 

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/indivior-announces-q1-2023-financial-results-301808955.html

SOURCE Indivior PLC

FAQ

What were Indivior's Q1 2023 financial results?

Indivior announced its Q1 2023 financial results on April 27, 2023, which can be accessed in detail on their website.

How is Indivior addressing substance use disorders?

Indivior is focused on transforming substance use disorders into recognized chronic diseases through its dedicated portfolio of treatments.

What is the significance of the earnings release for INVVY?

The earnings release provides insights into Indivior's financial performance, which is crucial for investors holding the INVVY stock.

When is Indivior's next earnings call?

Indivior's next earnings call will be held live on April 27, 2023, at 13:00 BST (8:00 am EST).